Facile generation of drug-like conformational antibodies specific for amyloid fibrils
- PMID: 40301692
- DOI: 10.1038/s41589-025-01881-9
Facile generation of drug-like conformational antibodies specific for amyloid fibrils
Abstract
Antibodies that recognize insoluble antigens, such as amyloid fibrils associated with neurodegenerative disorders, are important for research, diagnostic and therapeutic applications. However, these types of antibodies are difficult to generate, typically require animal immunization and also commonly require humanization in the case of therapeutic applications. Here we report a methodology for generating high-quality, fully human, conformation-specific antibodies against amyloid fibrils using a published human nonimmune library, yeast-surface display and quantitative fluorescence-activated cell sorting. Notably, this approach enables the isolation of conformation-specific antibodies against tau fibrils (Alzheimer's disease) and α-synuclein fibrils (Parkinson's disease) with combinations of high affinity, high conformational specificity and, in some cases, low off-target binding that rival or exceed those of clinical-stage antibodies specific for tau (zagotenemab) and α-synuclein (cinpanemab). This approach is expected to simplify the generation of conformation-specific antibodies against diverse protein aggregates and other insoluble antigens.
© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: P.M.T. is a member of the scientific advisory boards for Nabla Bio, Aureka Biotechnologies and Dualitas Therapeutics. The remaining authors declare no competing interests.
Update of
-
Flow cytometric isolation of drug-like conformational antibodies specific for amyloid fibrils.bioRxiv [Preprint]. 2023 Jul 4:2023.07.04.547698. doi: 10.1101/2023.07.04.547698. bioRxiv. 2023. Update in: Nat Chem Biol. 2025 Jun;21(6):916-925. doi: 10.1038/s41589-025-01881-9. PMID: 37461643 Free PMC article. Updated. Preprint.
Similar articles
-
Flow cytometric isolation of drug-like conformational antibodies specific for amyloid fibrils.bioRxiv [Preprint]. 2023 Jul 4:2023.07.04.547698. doi: 10.1101/2023.07.04.547698. bioRxiv. 2023. Update in: Nat Chem Biol. 2025 Jun;21(6):916-925. doi: 10.1038/s41589-025-01881-9. PMID: 37461643 Free PMC article. Updated. Preprint.
-
α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients.PLoS One. 2011 Apr 25;6(4):e18513. doi: 10.1371/journal.pone.0018513. PLoS One. 2011. PMID: 21541339 Free PMC article.
-
Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity.J Biol Chem. 2021 Jan-Jun;296:100508. doi: 10.1016/j.jbc.2021.100508. Epub 2021 Mar 4. J Biol Chem. 2021. PMID: 33675750 Free PMC article.
-
Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Neurotherapeutics. 2016 Jan;13(1):179-89. doi: 10.1007/s13311-015-0397-z. Neurotherapeutics. 2016. PMID: 26494242 Free PMC article. Review.
-
Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases.FEBS J. 2018 Oct;285(19):3631-3644. doi: 10.1111/febs.14587. Epub 2018 Aug 21. FEBS J. 2018. PMID: 29924502 Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources